MX2022001947A - Anticuerpos que se unen a las proteinas lrp5 y metodos de uso. - Google Patents

Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.

Info

Publication number
MX2022001947A
MX2022001947A MX2022001947A MX2022001947A MX2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A
Authority
MX
Mexico
Prior art keywords
antibodies
bind
methods
lrp5
lrp5 proteins
Prior art date
Application number
MX2022001947A
Other languages
English (en)
Inventor
Jagath R Junutula
Stephane Angers
Sachdev Sidhu
Guohua Pan
Nish Patel
Jason Moffat
Jarrett Adams
Original Assignee
Modmab Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modmab Therapeutics Inc filed Critical Modmab Therapeutics Inc
Publication of MX2022001947A publication Critical patent/MX2022001947A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En el presente documento se proporcionan anticuerpos que se unen específicamente a LRP5 y un método de uso de los mismos.
MX2022001947A 2019-08-14 2020-08-14 Anticuerpos que se unen a las proteinas lrp5 y metodos de uso. MX2022001947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962886913P 2019-08-14 2019-08-14
PCT/CA2020/051119 WO2021026665A1 (en) 2019-08-14 2020-08-14 Antibodies that bind to lrp5 proteins and methods of use

Publications (1)

Publication Number Publication Date
MX2022001947A true MX2022001947A (es) 2022-06-14

Family

ID=74570326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001947A MX2022001947A (es) 2019-08-14 2020-08-14 Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.

Country Status (10)

Country Link
US (1) US20230183336A1 (es)
EP (1) EP4013791A4 (es)
JP (1) JP2022544308A (es)
KR (1) KR20220078568A (es)
CN (1) CN114599679A (es)
AU (1) AU2020329092A1 (es)
CA (1) CA3147827A1 (es)
IL (1) IL290509A (es)
MX (1) MX2022001947A (es)
WO (1) WO2021026665A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2024007008A2 (en) * 2022-06-30 2024-01-04 The University Of Chicago Cd73 (nt5e) targeting polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
CN104066449B (zh) * 2012-01-18 2018-04-27 霍夫曼-拉罗奇有限公司 抗lrp5抗体及使用方法
WO2014100760A2 (en) * 2012-12-21 2014-06-26 Stowers Institute For Medical Research Antibodies for modulating binding between lrp and wise
TWI734719B (zh) * 2015-12-04 2021-08-01 德商百靈佳殷格翰國際股份有限公司 在腫瘤細胞中拮抗ｗｎｔ信號傳遞之雙抗體結合部位（ｂｉｐａｒａｔｏｐｉｃ）多肽
AU2018276409A1 (en) * 2017-05-31 2019-10-31 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
EP3625263A4 (en) * 2017-10-27 2021-05-05 New York University ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
JP7317016B2 (ja) * 2017-12-19 2023-07-28 スロゼン オペレーティング， インコーポレイテッド 抗ｌｒｐ５／６抗体及び使用方法

Also Published As

Publication number Publication date
IL290509A (en) 2022-04-01
AU2020329092A1 (en) 2022-03-31
CA3147827A1 (en) 2021-02-18
US20230183336A1 (en) 2023-06-15
JP2022544308A (ja) 2022-10-17
EP4013791A1 (en) 2022-06-22
KR20220078568A (ko) 2022-06-10
CN114599679A (zh) 2022-06-07
EP4013791A4 (en) 2024-01-24
WO2021026665A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
MX2021003393A (es) Proteinas de fijacion a sirp alfa y metodos de uso de estas.
PH12018501882A1 (en) Binding proteins and methods of use thereof
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
BR112018067458A2 (pt) anticorpos para tigit
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CR20210010A (es) Anticuerpos dirigidos contra il-11ra
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA201992460A1 (ru) Антитела-агонисты btla и их применение
SG10201801219VA (en) Anti-HER2 Antibodies
MY184189A (en) Methods of treating nail and scalp psoriasis
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.
EP4013790A4 (en) ANTIBODIES BINDING TO LRP6 PROTEINS AND METHODS OF USE
EA202092279A1 (ru) Антитела к mica и/или micb и их применение
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения